BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23895425)

  • 1. Functional analysis and in vitro correction of splicing FAH mutations causing tyrosinemia type I.
    Pérez-Carro R; Sánchez-Alcudia R; Pérez B; Navarrete R; Pérez-Cerdá C; Ugarte M; Desviat LR
    Clin Genet; 2014 Aug; 86(2):167-71. PubMed ID: 23895425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in the fumarylacetoacetate hydrolase gene causing hereditary tyrosinemia type I: overview.
    St-Louis M; Tanguay RM
    Hum Mutat; 1997; 9(4):291-9. PubMed ID: 9101289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two novel FAH gene mutations in a patient with hereditary tyrosinemia type I.
    Choi HJ; Bang HI; Ki CS; Lee SY; Kim JW; Song J; Shin MR; Lee YW; Lee DH; Park HD
    Ann Clin Lab Sci; 2014; 44(3):317-23. PubMed ID: 25117105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A missense mutation (Q279R) in the fumarylacetoacetate hydrolase gene, responsible for hereditary tyrosinemia, acts as a splicing mutation.
    Dreumont N; Poudrier JA; Bergeron A; Levy HL; Baklouti F; Tanguay RM
    BMC Genet; 2001; 2():9. PubMed ID: 11476670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1.
    Aponte JL; Sega GA; Hauser LJ; Dhar MS; Withrow CM; Carpenter DA; Rinchik EM; Culiat CT; Johnson DK
    Proc Natl Acad Sci U S A; 2001 Jan; 98(2):641-5. PubMed ID: 11209059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterozygosity for an exon 12 splicing mutation and a W234G missense mutation in an American child with chronic tyrosinemia type 1.
    Hahn SH; Krasnewich D; Brantly M; Kvittingen EA; Gahl WA
    Hum Mutat; 1995; 6(1):66-73. PubMed ID: 7550234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and functional characterization of a novel homozygous intronic variant in the fumarylacetoacetate hydrolase gene in a Chinese patient with tyrosinemia type 1.
    Chen J; Sun J; Li X; Du M
    BMC Med Genomics; 2022 Dec; 15(1):251. PubMed ID: 36463171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct sequencing of FAH gene in Pakistani tyrosinemia type 1 families reveals a novel mutation.
    Ijaz S; Zahoor MY; Imran M; Afzal S; Bhinder MA; Ullah I; Cheema HA; Ramzan K; Shehzad W
    J Pediatr Endocrinol Metab; 2016 Mar; 29(3):327-32. PubMed ID: 26565546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Splicing mutations, mainly IVS6-1(G>T), account for 70% of fumarylacetoacetate hydrolase (FAH) gene alterations, including 7 novel mutations, in a survey of 29 tyrosinemia type I patients.
    Arranz JA; Piñol F; Kozak L; Pérez-Cerdá C; Cormand B; Ugarte M; Riudor E
    Hum Mutat; 2002 Sep; 20(3):180-8. PubMed ID: 12203990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extensive in silico analysis of NF1 splicing defects uncovers determinants for splicing outcome upon 5' splice-site disruption.
    Wimmer K; Roca X; Beiglböck H; Callens T; Etzler J; Rao AR; Krainer AR; Fonatsch C; Messiaen L
    Hum Mutat; 2007 Jun; 28(6):599-612. PubMed ID: 17311297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries.
    Bergman AJ; van den Berg IE; Brink W; Poll-The BT; Ploos van Amstel JK; Berger R
    Hum Mutat; 1998; 12(1):19-26. PubMed ID: 9633815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compound mutations (R237X and L375P) in the fumarylacetoacetate hydrolase gene causing tyrosinemia type I in a Chinese patient.
    Cao YY; Zhang YL; DU J; Qu YJ; Zhong XM; Bai JL; Song F
    Chin Med J (Engl); 2012 Jun; 125(12):2132-6. PubMed ID: 22884142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Unique Spectrum of Mutations in Patients with Hereditary Tyrosinemia Type 1 in Different Regions of the Russian Federation.
    Baydakova GV; Ivanova TA; Mikhaylova SV; Saydaeva DK; Dzhudinova LL; Akhlakova AI; Gamzatova AI; Bychkov IO; Zakharova EY
    JIMD Rep; 2019; 45():89-93. PubMed ID: 30414057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presence of three mutations in the fumarylacetoacetate hydrolase gene in a patient with atypical symptoms of hereditary tyrosinemia type I.
    Morrow G; Dreumont N; Bourrelle-Langlois M; Roy V; Tanguay RM
    Mol Genet Metab; 2019 May; 127(1):58-63. PubMed ID: 30954369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a combined missense/splice-site mutation in FAH causing tyrosinemia type 1.
    Haghighi-Kakhki H; Rezazadeh J; Ahmadi-Shadmehri A
    J Pediatr Endocrinol Metab; 2014 Jul; 27(7-8):795-8. PubMed ID: 24756054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hereditary tyrosinemia type 1: novel missense, nonsense and splice consensus mutations in the human fumarylacetoacetate hydrolase gene; variability of the genotype-phenotype relationship.
    Ploos van Amstel JK; Bergman AJ; van Beurden EA; Roijers JF; Peelen T; van den Berg IE; Poll-The BT; Kvittingen EA; Berger R
    Hum Genet; 1996 Jan; 97(1):51-9. PubMed ID: 8557261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete rescue of lethal albino c14CoS mice by null mutation of 4-hydroxyphenylpyruvate dioxygenase and induction of apoptosis of hepatocytes in these mice by in vivo retrieval of the tyrosine catabolic pathway.
    Endo F; Kubo S; Awata H; Kiwaki K; Katoh H; Kanegae Y; Saito I; Miyazaki J; Yamamoto T; Jakobs C; Hattori S; Matsuda I
    J Biol Chem; 1997 Sep; 272(39):24426-32. PubMed ID: 9305902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro splicing analysis showed that availability of a cryptic splice site is not a determinant for alternative splicing patterns caused by +1G-->A mutations in introns of the dystrophin gene.
    Habara Y; Takeshima Y; Awano H; Okizuka Y; Zhang Z; Saiki K; Yagi M; Matsuo M
    J Med Genet; 2009 Aug; 46(8):542-7. PubMed ID: 19001018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Aspects of the FAH Mutations Involved in HT1 Disease.
    Morrow G; Angileri F; Tanguay RM
    Adv Exp Med Biol; 2017; 959():25-48. PubMed ID: 28755182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mildly elevated succinylacetone and normal liver function in compound heterozygotes with pathogenic and pseudodeficient
    Yang H; Rossignol F; Cyr D; Laframboise R; Wang SP; Soucy JF; Berthier MT; Giguère Y; Waters PJ; Mitchell GA;
    Mol Genet Metab Rep; 2018 Mar; 14():55-58. PubMed ID: 29326876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.